+ Watch HTWR
on My Watchlist
New device, which is a less invasive, miniaturized device to treat heart failure and has been active in Europe for years just received approval from an FDA Advisory committee, a good sign that it will receive full FDA approval soon and begun being sold in the US. Only one competitor on the market in this area and HTWR has the better product once it is released in the US.
Heartware's next gen. LVAD device is smaller with longer life than it's competitors. Given the epidemic of heart disease that exists, LVAD surgery is only going to grow and destination LVADs may be in the future.
Cramer 3/18/2011. Pointed out the new LVAD might come on line 3Q or 4Q 2012, FDA willing; that it requires only thoracotomy and pericardial insertion, rather than sternal cracking; and 90% survival over the rival device, Thoratec, which has 78%. Destination therapy was another point, as opposed to bridge-to-transplant, which Cramer sees online in 2013.Good enough to buy a spot on my CAPS list. Will be doing some DD on this in the next couple weeks for the real money account.
Insiders selling on recent run up. Still doesn't appear to be any profit for HTWR. I think a correction is due.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions